BioCurex, Inc.(fka BOCX)

[mysscat]

Okay... According to report filed today: o has developed a cancer detection kit for tissues (Histo-RECAF(TM)) which stains cancer cells thereby allowing a pathologist to easily see the cancer cells with the use of a microscope,

o has developed the Cryo-RECAF(TM) diagnostic kit which can be used by pathologists as an aid in determining whether cancer cells are benign or malignant during surgery, and

o is working on the development of a screening assay which can detect multiple cancers from a blood (serum) sample.

The FDA, in its device listing database, shows the Histo-RECAF(TM) kit as a Class I medical device. As a Class I medical device the Histo-RECAF(TM) kits may be sold in the United States as a staining test for AFP receptors (a.k.a. RECAF) in tissues. Biocurex has not applied to the FDA, Canada's Health Products and Food Branch, or any other regulatory authority for permission to sell the Cryo-RECAF(TM) kit on a commercial basis. Due to the costs involved in manufacturing and marketing, Biocurex plans to license its Histo-RECAF(TM) and Cryo-RECAF(TM) technology to third parties. As of October 31, 2007 Biocurex had not sold any Histo-RECAF(TM) or Cryo-RECAF(TM) test kits and had not licensed the technology pertaining to these kits to any third parties.

BioCurex has developed a serum based cancer screening assay and has licensed certain aspects of the serum assay technology to Abbott Laboratories. The Licensing Agreement with Abbott is semi-exclusive thus allowing for more than one licensee. Biocurex expects to enter into other licensing agreements in the coming months. BioCurex retained all rights to its prototype format, a radio-immunoassay (RIA), which it plans to commercialize directly to clinical laboratories as ASRs ("Analyte Specific Reagents") for production of "home-brew" tests. A home-brew test is a test developed by a clinical laboratory using one or more ASRs, general laboratory reagents and/or general laboratory instruments for diagnostic purposes. The FDA classifies ASRs based on risks to public health and allows clinical laboratories to use certain individual reagents in their own in-house developed (home-brew) tests, without requiring manufacturers to submit
510(k)s or PMAs for the majority of individual reagents. This regulation could allow clinical laboratories to produce RECAF tests based on Biocurex's RIA without the need for a lengthy FDA approval process. For more information visit http://www.aacc.org/govt/asr.htm.

During the twelve months ended September 30, 2008 Biocurex:

o will continue its efforts to license the Histo-Recaf technology to third parties.

o plans to enter into agreements relating to its RIA blood test with clinical laboratories using ASRs.

o intends to license its Serum-RECAF(TM) to other major bio-pharma companies.

o if necessary, will continue to raise capital through the sale of its common stock or securities convertible into common stock in order to fund Biocurex's operations and research and development.

o continue research in the areas of therapeutics and imagery.

After reading the financials I think they are quite savy in acquiring financing. I expect their timeline is to have all completed by 2010 when remainder of payment of notes are due. That's in 2 years....